Sandbox:skorjian2: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) (Blanked the page) |
Sergekorjian (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
‘’’Adjuvant therapy’’’ | |||
# Interferon alfa-2a (Roferon-A) | |||
# Interferon alfa-2b (Intron-A) | |||
# Peginterferon alfa-2b (Sylatron) | |||
‘’’Metastatic or unresectable disease’’’ | |||
:* ‘’’’’Single Agent Chemotherapy’’’’’ | |||
::# Dabrafenib (Tafinlar) | |||
::# Dacarbazine (DTIC) | |||
::# Docetaxel (Taxotere) | |||
::# High-dose (HD) IL-2 | |||
::# IL-2 maintenance biotherapy | |||
::# Imatinib (Gleevec) | |||
::# Ipilimumab (Yervoy) | |||
::# Nivolumab (Opdivo) | |||
::# Paclitaxel (Taxol) | |||
::# Pembrolizumab (Keytruda) | |||
::# Temozolomide (Temodar) | |||
::# Trametinib (Mekinist) | |||
::# Vemurafenib (Zelboraf) | |||
:* ‘’’’’Combination Chemotherapy’’’’’ | |||
::# Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC) | |||
::# Carboplatin + Paclitaxel (CP) | |||
::# Carboplatin + Paclitaxel + nanoparticle albumin-bound | |||
::# Carboplatin + Paclitaxe +, Sorafenib | |||
::# Cisplatin + Dacarbazine ± Carmustine | |||
::# Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine | |||
::# Cisplatin + Paclitaxel + Dacarbazine | |||
::# Cisplatin + Vinblastine + Dacarbazine (CVD) | |||
::# CVD + IL-2 + IFN alfa-2b (sequential biochemotherapy) | |||
::# Temozolomide + Bevacizumab (TB) | |||
::# Dabrafenib + Trametinib | |||
::# Ipilimumab + Dacarbazine | |||
::# Ipilimumab + Nivolumab |
Revision as of 01:21, 22 August 2015
‘’’Adjuvant therapy’’’
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- Peginterferon alfa-2b (Sylatron)
‘’’Metastatic or unresectable disease’’’
- ‘’’’’Single Agent Chemotherapy’’’’’
- Dabrafenib (Tafinlar)
- Dacarbazine (DTIC)
- Docetaxel (Taxotere)
- High-dose (HD) IL-2
- IL-2 maintenance biotherapy
- Imatinib (Gleevec)
- Ipilimumab (Yervoy)
- Nivolumab (Opdivo)
- Paclitaxel (Taxol)
- Pembrolizumab (Keytruda)
- Temozolomide (Temodar)
- Trametinib (Mekinist)
- Vemurafenib (Zelboraf)
- ‘’’’’Combination Chemotherapy’’’’’
- Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
- Carboplatin + Paclitaxel (CP)
- Carboplatin + Paclitaxel + nanoparticle albumin-bound
- Carboplatin + Paclitaxe +, Sorafenib
- Cisplatin + Dacarbazine ± Carmustine
- Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine
- Cisplatin + Paclitaxel + Dacarbazine
- Cisplatin + Vinblastine + Dacarbazine (CVD)
- CVD + IL-2 + IFN alfa-2b (sequential biochemotherapy)
- Temozolomide + Bevacizumab (TB)
- Dabrafenib + Trametinib
- Ipilimumab + Dacarbazine
- Ipilimumab + Nivolumab